Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Apogee Therapeutics Inc.

RBC Capital analyst Brian Abrahams maintained a Buy rating on Apogee Therapeutics on November 10 and set a price target of $70.00. The company’s sh...

RBC Capital Sticks to Their Buy Rating for Apogee Therapeutics (APGE)

Mizuho Securities analyst Joseph Catanzaro maintained a Buy rating on Apogee Therapeutics today and set a price target of $105.00. Catanzaro covers...

Mizuho Securities Sticks to Their Buy Rating for Apogee Therapeutics (APGE)

In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Apogee Therapeutics, with a price target of $115.00. The compa...

Apogee Therapeutics (APGE) Receives a Buy from BTIG

The latest update is out from Apogee Therapeutics ( ($APGE) ). On November 10, 2025, Apogee Therapeutics announced positive interim Phase 1 results...

Apogee Therapeutics Announces Positive Phase 1 Results

In a report released on October 27, Joseph Catanzaro from Mizuho Securities maintained a Buy rating on Apogee Therapeutics. The company’s shares cl...

Market Cap	$3.02B	P/E Ratio	N/A
52W High	$67.66	52W Low	$26.20
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	96.6%
Overall Score	60	Value Score	55
Quality Score	--	Technical Score	66

EPS Current Est	$-4.06	EPS Next Est	$-4.16
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	APGE	$66.26	+4.56%	625.60K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	APGE	$66.26	+4.6%	625.60K
3
4
5
6

APGE

APGE

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Apogee Therapeutics Inc. Data in Excel

Get Apogee Therapeutics Inc. Data in Excel